ClinicalTrials.gg
CompletedNCT07573813Updated May 7, 2026

Novel SaCoVLM™ Video Laryngeal Mask Airway as an Intubation Conduit in Morbidly Obese Bariatric Surgery

An observational study in Obesity and Morbidly Obese, sponsored by Yongtao Sun. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Yongtao Sun · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
57
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 603 studies in Obesity with a site in China — 223 open to participants now, 284 under way, 67 of them phase 3. Obesity · China.

Enrollment
92nd of 99
57 · median 320
Started
2022
with 40 others
Observational
99 of 603
37 open now
Registered
487th of 603
by date

Among the 603 studies in Obesity with a site in China, this one is the 92nd largest by enrollment of the 99 observational ones that give a count, is one of 41 that started in 2022, is one of 99 observational ones, and was the 487th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

223 of the 603 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

218 more — sign in →

All 223 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

Background: The SaCoVLM™ video laryngeal mask is a novel video-assisted device that integrates the functions of both a dual-channel laryngeal mask airway (LMA) and an intubating laryngeal mask airway (ILMA). At present, there are relatively few studies on awake airway management for obese patients who undergo laparoscopic sleeve gastrectomy (LSG). To evaluate the efficacy and safety of the SaCoVLM™ video laryngeal mask airway as an intubation conduit in morbidly obese patients undergoing laparoscopic sleeve gastrectomy.

Patients and methods: This single-arm prospective study evaluated the efficacy and safety of the SaCoVLM™ video laryngeal mask airway in 57 morbidly obese patients (BMI ≥35 kg/m²) undergoing LSG.

Read the detailed description

All anesthesiologists in this study underwent centralized training prior to trial initiation, with documented certification in protocol-specific procedures. No preoperative medications were administered to any patients. Upon entering the operating room, patients were positioned in a semi-fowler position, with intravenous access established. Standard monitoring protocols were implemented, including electrocardiography (ECG), heart rate (HR), non-invasive blood pressure (NIBP), pulse oximetry (SpO₂), end-tidal carbon dioxide (EtCO₂), and bispectral index (BIS), alongside radial artery catheterization for invasive blood pressure monitoring. All patients underwent awake insertion of the SaCoVLM™, with surgery completed under general anesthesia combining the video laryngeal mask and endotracheal intubation.

Immediately upon arrival in the operating room, patients were instructed to hold 10 mL of dyclonine mucilage orally for approximately 10 minutes to achieve topical anesthesia. Premedication included midazolam 2 mg and atropine 0.4 mg, followed by bilateral ultrasound-guided superior laryngeal nerve block using 0.375% ropivacaine. A properly sized laryngeal mask was selected, and under awake conditions, patients were instructed to open their mouths to facilitate SaCoVLM™. Optimal positioning was confirmed by visualization of complete glottic structures on the monitor screen. The glottic exposure grade was as we previously described. The cuff was inflated using a handheld manometer, and the mask was connected to the anesthesia machine. Clear glottic visualization on the monitor and the presence of a regular EtCO₂ waveform confirmed proper mask alignment, after which rapid anesthesia induction was initiated.

If suboptimal positioning occurred, the up-down maneuver, cricoid pressure, cuff pressure adjustment, fiberoptic bronchoscopy-guided intubation were applied for minor adjustments. Under direct video guidance, the endotracheal tube was gently advanced along the natural curvature of the airway. Successful intubation was defined by unimpeded tube passage, direct visualization of tracheal entry, and sustained EtCO₂ waveform. Following intubation, the breathing circuit was immediately connected, and bilateral lung auscultation confirmed symmetrical breath sounds before securing both the mask and endotracheal tube. Intraoperative fluid administration and vasoactive medications were adjusted based on vital signs, urine output, and physiological requirements.

Postoperatively, the endotracheal tube was removed under deep anesthesia, and the video laryngeal mask was retained for transfer to the post-anesthesia care unit (PACU). The laryngeal mask was removed only after patients regained adequate spontaneous respiration, demonstrated responsiveness to verbal commands, and met established extubation criteria.

03

Conditions studied

  • Obesity
  • Morbidly Obese

Browse trials for

Keywords

  • Video laryngeal mask airway
  • Morbidly obese patients
  • Airway management
  • Laparoscopic sleeve gastrectomy
  • First-attempt success rate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population comprised adult patients aged over 18 years (with no upper age limit) diagnosed with morbid obesity.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients aged over 18 years (no upper age limit)
  2. Diagnosed with morbid obesity, clinically defined as either:

(BMI) ≥ 40 kg/m², or BMI ≥ 35 kg/m² accompanied by at least one significant obesity-related comorbidity

Exclusion criteria

Exclusion Criteria:

  1. Have no clinical indicators of anticipated difficult airway (Mallampati classification IV, thyromental distance \< 6 cm, mouth opening \< 3 cm, severe limited neck extension, or a history of difficult airway management)
  2. Demonstrate tolerance for laparoscopic surgery and anesthesia
  3. Be scheduled exclusively for LSG without concurrent additional procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
57 participants (actual)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • morbidly obese bariatric surgery

    This study was a single-arm prospective study, so there was no grouping.

    Device: SaCoVLM™ in Difficult Airways

Interventions

  • DeviceSaCoVLM™ in Difficult Airways

    As part of the awake airway management protocol initiated in the operating room, patients were first instructed to hold 10 mL of dyclonine mucilage orally for approximately 10 minutes to achieve topical oropharyngeal anesthesia. This was followed by intravenous administration of midazolam 2 mg and atropine 0.4 mg, and bilateral ultrasound-guided superior laryngeal nerve block using 0.375% ropivacaine. A properly sized laryngeal mask was selected. The posterior surface of the cuff was lubricated with a water-based surgical lubricant. Under awake conditions, patients were instructed to open their mouths to facilitate SaCoVLM™ insertion. Optimal positioning was confirmed by visualization of complete glottic structures on the monitor screen. The glottic exposure grade was as we previously described . The cuff was inflated using a handheld manometer, and the mask was connected to the anesthesia machine. Clear glottic visualization on the monitor and the presence of a regular EtCO₂ waveform.

  • DeviceSaCoVLM™ in Difficult Airways

    As part of the awake airway management protocol initiated in the operating room, patients were first instructed to hold 10 mL of dyclonine mucilage orally for approximately 10 minutes to achieve topical oropharyngeal anesthesia. This was followed by intravenous administration of midazolam 2 mg and atropine 0.4 mg, and bilateral ultrasound-guided superior laryngeal nerve block using 0.375% ropivacaine. A properly sized laryngeal mask was selected. The posterior surface of the cuff was lubricated with a water-based surgical lubricant. Under awake conditions, patients were instructed to open their mouths to facilitate SaCoVLM™ insertion. Optimal positioning was confirmed by visualization of complete glottic structures on the monitor screen. The glottic exposure grade was as we previously described. The cuff was inflated using a handheld manometer, and the mask was connected to the anesthesia machine. Clear glottic visualization on the monitor and the presence of a regular EtCO₂ waveform.

06

What researchers measure

Primary outcomes

  1. the first-time success rate of intubation after insertion of SaCoVLM™

    Time frame: Within 10 minutes following SaCoVLM™ placement

Secondary outcomes

  1. Time to Successful SaCoVLM™ Insertion (seconds)

    Time to successful insertion is measured in seconds as a continuous time-to-event variable. Successful insertion is defined as proper placement of the SaCoVLM™ with visible chest rise and a square-wave capnography trace. Shorter time indicates a better outcome (faster airway establishment). The primary metric reported will be the median insertion time with interquartile range, along with the proportion of successful insertions within 60, 90, and 120 seconds.

    Time frame: From the start of device insertion into the mouth until the time of successful SaCoVLM™ placement with first confirmed ventilation, assessed up to 120 seconds. If insertion is not successful within 120 seconds, the event is censored at 120 seconds.

  2. Number of SaCoVLM™ Insertion Attempts per Participant

    An insertion attempt is defined as any entry of the SaCoVLM™ into the patient's mouth with the intention of placement, regardless of depth or success. Each withdrawal of the device from the mouth followed by re-entry counts as a new attempt. The total number of attempts required to achieve successful placement (confirmed by end-tidal CO₂ waveform) is recorded. Fewer attempts indicate a better outcome (easier insertion). The primary metric reported will be the mean (or median) number of attempts, the range, and the proportion of participants requiring 1, 2, or ≥3 attempts.

    Time frame: From the first insertion attempt until successful SaCoVLM™ placement is achieved or until the procedure is abandoned, assessed during the initial airway management procedure (up to 120 seconds or a maximum of 3 attempts, whichever comes first).

  3. the SaCoVLM™ glottic exposure grades

    Time frame: Immediately after SaCoVLM™ placement

  4. Oropharyngeal Leak Pressure (OLP) (cm H₂O)

    OLP is measured by closing the adjustable pressure limiting valve of the anesthesia circuit while maintaining a fixed gas flow of 3 L/min. The airway pressure at which an audible leak occurs around the device (or the pressure at which the capnography waveform flattens) is recorded as the OLP in cm H₂O. Higher OLP indicates a better seal and is considered a better outcome (more effective supraglottic airway seal). The primary metric reported will be the mean (or median) OLP with standard deviation or interquartile range.

    Time frame: Immediately after successful SaCoVLM™ insertion and before start of positive pressure ventilation (measured at a single time point: within 1 minute of confirmation of correct placement)

  5. Proportion of Participants Requiring Any Airway Optimization Maneuver During SaCoVLM™ Placement

    The airway optimization protocol includes predefined maneuvers to improve ventilation or seal when SaCoVLM™ placement is suboptimal (e.g., audible leak \>30 cm H₂O, absent capnography, or inability to ventilate). Recorded maneuvers may include: chin lift, jaw thrust, head extension/flexion, device rotation, partial withdrawal and reinsertion, or changing to a different size/type of supraglottic airway. The primary outcome metric is the proportion of participants requiring any optimization maneuver during the specified time frame. Secondary metrics include the number of different maneuvers used per participant and the specific maneuvers most frequently applied. No numerical scale is used; this is a descriptive/binary outcome (optimization required: yes/no). Fewer required maneuvers indicate a better outcome (easier device placement).

    Time frame: During the initial airway management procedure, from the start of the first insertion attempt until successful ventilation is confirmed (assessed up to 120 seconds or a maximum of 3 attempts).

  6. Incidence and Severity of Postoperative Sore Throat (POST) as Assessed by a 4-Point Scale

    POST is measured using a 4-point categorical scale: 0 = no sore throat 1. = mild sore throat (complains only when asked) 2. = moderate sore throat (complains spontaneously) 3. = severe sore throat (hoarseness or difficulty swallowing) Minimum value = 0, maximum value = 3. Higher scores indicate a worse outcome (more severe sore throat). The primary metrics reported will be: Incidence = proportion of participants with any POST (score ≥1) at the specified time point Severity = mean (or median) score at each time point, plus the proportion with severe POST (score 3)

    Time frame: At 72 hours after the end of surgery

  7. Incidence and Severity of Postoperative Hoarseness as Assessed by a 4-Point Scale

    Postoperative hoarseness is measured using a 4-point categorical scale: 0 = no hoarseness (voice normal) 1. = mild hoarseness (voice slightly different but able to speak without difficulty) 2. = moderate hoarseness (voice obviously changed, speaking with effort) 3. = severe hoarseness (voice barely audible or aphonic)

    Time frame: At 24 hours after the end of surgery

  8. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

    Adverse events (AEs) are defined according to \[specify system, e.g., Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 or a standardized surgical complication list\]. AEs include, but are not limited to: hypoxia, bradycardia, hypotension, laryngospasm, bronchospasm, dental trauma, bleeding, and allergic reaction. Each AE is graded for severity (mild/moderate/severe) and relationship to the procedure. The primary metric reported will be the proportion of participants experiencing at least one AE during the specified time frame. Secondary metrics include the total number of AEs, type and frequency of specific AEs, and proportion of severe AEs. No scale is used for the primary binary outcome; severity grading follows CTCAE (Grade 1-5, where higher grade = worse outcome).

    Time frame: From the end of surgery until 72 hours postoperatively

07

Study locations

1 site
  • The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
    Jinan, Shandong 250014, China
08

References and documents

Publications

  • Harjai M, Alam S, Rastogi S, Kumar S. Effectiveness and Validity of Preoperative Ultrasonographic Airway Assessment and Clinical Screening Tests to Predict Difficult Laryngoscopy: A Prospective, Observational Study. Cureus. 2023 Jul 15;15(7):e41933. doi: 10.7759/cureus.41933. eCollection 2023 Jul. PubMed 37583718 ↗
  • Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and Risks of Bariatric Surgery in Adults: A Review. JAMA. 2020 Sep 1;324(9):879-887. doi: 10.1001/jama.2020.12567. PubMed 32870301 ↗
  • Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669-2701. doi: 10.2337/dci18-0033. Epub 2018 Oct 4. PubMed 30291106 ↗
  • Wang Y, Zhao L, Gao L, Pan A, Xue H. Health policy and public health implications of obesity in China. Lancet Diabetes Endocrinol. 2021 Jul;9(7):446-461. doi: 10.1016/S2213-8587(21)00118-2. Epub 2021 Jun 4. PubMed 34097869 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — all IPD collected throughout the trial, only IPD used in the results publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: From May 2022 to May 2023, we included a total of 57 patients who were scheduled to undergo bariatric surgery.

Access criteria: Who Qualified researchers from academic, non-profit, or commercial institutions with an approved research proposal; regulatory authorities; and direct collaborators. What Anonymized IPD, data dictionary, protocol, SAP, and ICF summary. No direct or indirect participant identifiers. How Submit proposal via online portal. Independent review committee approval. Sign data use agreement (non-identification, non-commercial, no third-party sharing). Access via secure virtual research environment or encrypted download; time-limited (e.g., 12 months); audit logs kept.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in May 2023, 12 months.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's 12 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
May 7, 2026
StartActual
May 1, 2022
Primary completionActual
May 20, 2023
CompletionActual
May 30, 2023
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07573813
Lead sponsor
Yongtao Sun
Responsible party
Yongtao Sun (Deputy Director, Qianfoshan Hospital) — Sponsor-investigator
First posted
May 7, 2026
Start date
May 1, 2022
Primary completion
May 20, 2023
Completion
May 30, 2023
Last update
May 7, 2026

Study contacts

Yongtao Sun
principal investigator · Shandong First Medical University
Min Zhang
study chair · Shandong First Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion